Flt3 ligand bioactivity and pharmacology in neoplasia.

Current drug targets. Immune, endocrine and metabolic disorders

Volumn 4, Issue 2, 2004, Pages 149-156

  Reber, A J ^a   Ashour, A E ^a   Robinson, S N ^a   Talmadge, J E ^a   Solheim, J C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD135 ANTIGEN; FLT3 LIGAND PROTEIN; IMMUNOLOGICAL ADJUVANT; LIGAND; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE;

ANIMAL; ARTICLE; METABOLISM; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; FMS-LIKE TYROSINE KINASE 3; LIGANDS; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 3142550897     PISSN: 15680088     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568008043339956     Document Type: Article

References (0)